The additive antinociceptive interaction between WIN 55,212-2, a cannabinoid agonist, and ketorolac

Basit Öğe Kaydı
dc.authoridozyigit, filiz/0000-0002-0062-4281
dc.authoridOzyigit, F/0000-0002-0062-4281
dc.authoridUlugol, Ahmet/0000-0003-4643-1124
dc.authorwosidozyigit, filiz/ABD-7066-2021
dc.authorwosidOzyigit, F/HJY-5447-2023
dc.authorwosidUlugol, Ahmet/V-9665-2019
dc.contributor.authorUlugöl, A
dc.contributor.authorÖzyigit, F
dc.contributor.authorYesilyurt, Ö
dc.contributor.authorDogrul, A
dc.date.accessioned2024-06-12T11:19:29Z
dc.date.available2024-06-12T11:19:29Z
dc.date.issued2006
dc.departmentTrakya Üniversitesien_US
dc.description.abstractCombinations of nonsteroidal antiinflammatory drugs (NSAIDs) and opioids are widespread in the management of pain, allowing better analgesia with reduced side effects. Cannabinoids are promising-analgesic drugs that have pharmacological properties similar to those of opioids. However, the beneficial effects of cannabinoids for pain treatment are counterbalanced by their psychotomimetic side effects. We designed the present study to evaluate the antinociceptive interaction between cannabinoids and NSAIDs in mice, using the acetic acid-induced writhing test and tail-flick test. Interactions were analyzed using isobolographic analysis. WIN 55,212-2, a cannabinoid agonist, and the NSAID ketorolac, either alone or in combination, produced dose-dependent antinociception in the writhing test. Isobolographic analysis showed additive interactions between WIN 55,212-2 and ketorolac when they were coadministered systemically. Ketorolac is inactive in the radiant heat tail-flick test in which WIN 55,212-2 was active. Ketorolac did not influence WIN 55,212-2-induced antinociception in the tail-flick test. This study demonstrated an additive antinociceptive interaction between WIN 55,212-2 and ketorolac in an inflammatory visceral pain model. The combination of cannabinoids and NSAIDs may have utility in the pharmacotherapy of pain.en_US
dc.identifier.doi10.1213/01.ane.0000194587.94260.1d
dc.identifier.endpage447en_US
dc.identifier.issn0003-2999
dc.identifier.issue2en_US
dc.identifier.pmid16428540en_US
dc.identifier.scopus2-s2.0-31444445712en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage443en_US
dc.identifier.urihttps://doi.org/10.1213/01.ane.0000194587.94260.1d
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25217
dc.identifier.volume102en_US
dc.identifier.wosWOS:000234912900023en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofAnesthesia And Analgesiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectNonsteroidal Antiinflammatory Drugsen_US
dc.subjectAnalgesic Interactionsen_US
dc.subjectNociceptionen_US
dc.subjectMorphineen_US
dc.subjectModelsen_US
dc.subjectPainen_US
dc.subjectMiceen_US
dc.subjectDelta(9)-Tetrahydrocannabinolen_US
dc.subjectInflammationen_US
dc.subjectInhibitionen_US
dc.titleThe additive antinociceptive interaction between WIN 55,212-2, a cannabinoid agonist, and ketorolacen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu